New NIH High-Risk, High-Reward Funding Opportunities on SARS-CoV-2 | NCCIH

New NIH High-Risk, High-Reward Funding Opportunities on SARS-CoV-2 | NCCIH

New NIH High-Risk, High-Reward Funding Opportunities on SARS-CoV-2

June 11, 2020

Emmeline Edwards, Ph.D.

The National Institutes of Health (NIH) is partnering with all sectors to ensure that safe, effective treatments and vaccines are available to help prevent devastating loss of life related to SARS-CoV-2, the novel coronavirus that causes COVID-19. I would like to bring to your attention two time-sensitive and important SARS-CoV-2 specific funding opportunity announcements (FOAs) issued by the High-Risk, High-Reward Research (HRHR) Program of the NIH Common Fund:

• NIH Director’s Emergency Transformative Research Award (R01 Clinical Trial Optional) (RFA-RM-20-020)
• NIH Director’s Emergency Early Independence Award (DP5 Clinical Trial Optional) (RFA-RM-20-021).

Research areas to be supported by these funding opportunities that would be of great interest to the National Center for Complementary and Integrative Health (NCCIH) include groundbreaking, exceptionally innovative, original, and/or unconventional research related to natural products and/or mind and body interventions and with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies to address the prevention of, preparation for, or response to coronavirus SARS-CoV-2. To learn more about NCCIH’s research objectives and strategies, please visit the NCCIH website.

Application deadlines are September 30, 2020 (RFA-RM-20-020) and September 4, 2020 (RFA-RM-20-021), respectively, by 5:00 p.m. local time of the applicant organization. The earliest start date of funded projects will be September 2021.